For example, when compared to placebo, semaglutide 1 mg per week, dulaglutide 1.5 mg per week and insulin degludec or insulin glargine 100 U ml−1, tirzepatide was more effective in reducing glycated hemoglobin (HbA1c) and weight in people with T2D over a 26−52-week treatment period5,6. This evidence concerns the gene INS and type 2 diabetes mellitus.